Nectar Lifesciences (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Nectar Lifesciences Limited |
|||
|
Price: ₹41.80 | ||
| 52 Week Low: ₹26.15 52 Week High: ₹56.50 |
|||
| Market Capital: 807.34 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Nectar Lifesciences Share Price Target For 2024
- 1.1.1: Nectar Lifesciences Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Nectar Lifesciences Share Price Target For 2025
- 1.2.1: Nectar Lifesciences Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Nectar Lifesciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Nectar Lifesciences Brief Company Overview
- 4: Nectar Lifesciences Financial Performance
- 4.0.1: Is Nectar Lifesciences A Good Buy For Long Term?
To predict the Nectar Lifesciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Nectar Lifesciences Share Price Target For 2024
The line chart displays the monthly closing prices of Nectar Lifesciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Nectar Lifesciences shares in 2024, see the table below.
Nectar Lifesciences Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 45.27 (+8.30%) | Price Action: Oct 2024 High |
| 2024 Target 2 | 44.04 (+5.35%) | Price Action: Sep 2014 High |
| 2024 Target 1 | 43.54 (+4.16%) | Price Action: 18 Dec 2024 High |
| Current Price | 41.80 | Nectar Lifesciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 40.99 (-1.94%) | Price Action: Sep 2016 High |
| Stop Loss 2 | 40.5 (-3.12%) | Price Action: May 2016 High |
| Stop Loss 3 | 40.0 (-4.31%) | Price Action: Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: Nectar Lifesciences is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹36.25 serves as the nearest technical reference point.
Historical Returns: 3-month: +3.16% | 6-month: +33.38% | 1-year: +30.02%
Nectar Lifesciences Share Price Target For 2025
The line chart displays the monthly closing prices of Nectar Lifesciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Nectar Lifesciences shares in 2025, see the table below.
Nectar Lifesciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 63.66 (+52.29%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 62.12 (+48.61%) | Price Action: Chart |
| 2025 Target 1 | 61.5 (+47.12%) | Fibonacci Extension Level 64.90% |
| Current Price | 41.80 | Nectar Lifesciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 37.21 (-10.99%) | Price Action: Jun 2010 High |
| Stop Loss 2 | 36.63 (-12.37%) | Price Action: Sep 2008 High |
| Stop Loss 3 | 36.25 (-13.28%) | Price Action: Feb 2010 High |
Long-Term Technical Outlook
52-Week Range Analysis: Nectar Lifesciences is currently trading at 51.6% of its 52-week range (₹26.15 - ₹56.5).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +30.02% | 3-year: +56.03% | 5-year: +244.88%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Nectar Lifesciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹41.80 | ||
| 2024 | ₹38.66 | -7.51% | ₹39.24 |
| 2025 | ₹42.58 | +10.14% | ₹43.22 |
| 2026 | ₹43.95 | +3.22% | ₹45.81 |
| 2027 | ₹48.90 | +11.26% | ₹51.05 |
| 2028 | ₹55.84 | +14.19% | ₹56.68 |
| 2029 | ₹59.01 | +5.68% | ₹59.90 |
| 2030 | ₹62.86 | +6.52% | ₹63.80 |
| 2031 | ₹63.05 | +0.30% | ₹66.79 |
| 2032 | ₹68.46 | +8.58% | ₹72.03 |
| 2033 | ₹76.53 | +11.79% | ₹77.68 |
| 2034 | ₹79.35 | +3.68% | ₹80.54 |
| 2035 | ₹83.14 | +4.78% | ₹84.39 |
| 2036 | ₹82.16 | -1.18% | ₹87.77 |
| 2037 | ₹88.02 | +7.13% | ₹93.01 |
| 2038 | ₹97.21 | +10.44% | ₹98.67 |
| 2039 | ₹94.54 | -2.75% | ₹98.34 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Nectar Lifesciences Brief Company Overview
Nectar Lifesciences Limited: A Pharmaceutical Powerhouse Established in 1995 and headquartered in Chandigarh, India, Nectar Lifesciences Limited is a leading manufacturer and distributor of pharmaceutical products, making its mark both domestically and internationally. The...
company boasts a diverse product portfolio that includes: Active Pharmaceutical Ingredients and Intermediates: Cefixime, cefuroxime axetil, cefotaxime sodium, ceftriaxone sodium, etc. Contract Manufacturing: Tablets, capsules, dry powder oral suspensions, granules, and injectables for cephalosporins. Menthol and Mint Derivatives: Essential oils and extracts. Empty Hard Gelatin Capsules: Essential components for pharmaceutical formulations. Nectar Lifesciences is renowned for its commitment to quality and innovation, earning a reputation as a trusted partner in the pharmaceutical industry.Nectar Lifesciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 807.34 Crore | Market valuation of Nectar Lifesciences's shares. |
| Revenue (TTM) | 1,649.3 Crore | Total revenue generated by Nectar Lifesciences over the past twelve months. |
| Net Income (TTM) | +61,437,000.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +6.78% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +0.37% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-8.90% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+63.10% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
59.43 | Company's total debt divided by total shareholder equity. |
| Total Debt | 635.53 Crore | Sum of Nectar Lifesciences's current & long-term financial obligations. |
| Total Cash | 20.3 Crore | Total amount of liquid funds available to Nectar Lifesciences. |
| Beta | 1.02 | Beta is greater than 1 indicating that the Nectar Lifesciences's price is more volatile than the market. |
Is Nectar Lifesciences A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
